Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Drug repurposing of metformin for Alzheimer’s disease: Combining causal inference in medical records data and systems pharmacology for biomarker identification

View ORCID ProfileMarie-Laure Charpignon, View ORCID ProfileBella Vakulenko-Lagun, View ORCID ProfileBang Zheng, Colin Magdamo, View ORCID ProfileBowen Su, View ORCID ProfileKyle Evans, View ORCID ProfileSteve Rodriguez, View ORCID ProfileArtem Sokolov, View ORCID ProfileSarah Boswell, View ORCID ProfileYi-Han Sheu, View ORCID ProfileMelek Somai, View ORCID ProfileLefkos Middleton, View ORCID ProfileBradley T. Hyman, View ORCID ProfileRebecca A. Betensky, View ORCID ProfileStan N. Finkelstein, View ORCID ProfileRoy E. Welsch, View ORCID ProfileIoanna Tzoulaki, View ORCID ProfileDeborah Blacker, View ORCID ProfileSudeshna Das, View ORCID ProfileMark W. Albers
doi: https://doi.org/10.1101/2021.08.10.21261747
Marie-Laure Charpignon
1Institute for Data, Systems, and Society, Massachusetts Institute of Technology, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marie-Laure Charpignon
Bella Vakulenko-Lagun
2Department of Statistics, University of Haifa, Mt Carmel, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bella Vakulenko-Lagun
Bang Zheng
3Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bang Zheng
Colin Magdamo
4Department of Neurology, Massachusetts General Hospital / Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bowen Su
5Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bowen Su
Kyle Evans
4Department of Neurology, Massachusetts General Hospital / Harvard Medical School, Boston, MA, USA
6Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kyle Evans
Steve Rodriguez
4Department of Neurology, Massachusetts General Hospital / Harvard Medical School, Boston, MA, USA
6Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Steve Rodriguez
Artem Sokolov
6Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Artem Sokolov
Sarah Boswell
6Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sarah Boswell
Yi-Han Sheu
7Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yi-Han Sheu
Melek Somai
8Inception Labs, Collaborative for Health Delivery Sciences, Medical College of Wisconsin, Wauwatosa, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Melek Somai
Lefkos Middleton
3Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lefkos Middleton
Bradley T. Hyman
4Department of Neurology, Massachusetts General Hospital / Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bradley T. Hyman
Rebecca A. Betensky
9Department of Biostatistics, School of Global Public Health, New York University, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rebecca A. Betensky
Stan N. Finkelstein
1Institute for Data, Systems, and Society, Massachusetts Institute of Technology, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stan N. Finkelstein
Roy E. Welsch
1Institute for Data, Systems, and Society, Massachusetts Institute of Technology, Cambridge, MA, USA
10Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Roy E. Welsch
Ioanna Tzoulaki
5Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
11Dementia Research Institute, Imperial College London, London, UK
12Deparment of Hygiene and Epidemiology, University of Ioannina, Ioannina, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ioanna Tzoulaki
  • For correspondence: albers.mark@mgh.harvard.edu
Deborah Blacker
7Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA
13Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Deborah Blacker
  • For correspondence: albers.mark@mgh.harvard.edu
Sudeshna Das
4Department of Neurology, Massachusetts General Hospital / Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sudeshna Das
  • For correspondence: albers.mark@mgh.harvard.edu
Mark W. Albers
4Department of Neurology, Massachusetts General Hospital / Harvard Medical School, Boston, MA, USA
6Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark W. Albers
  • For correspondence: albers.mark@mgh.harvard.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Metformin, an antidiabetic drug, triggers anti-aging cellular responses. Aging is the principal risk factor for dementia, but previous observational studies of the diabetes drugs metformin vs. sulfonylureas have been mixed. We tested the hypotheses that metformin improves survival and reduces the risk of dementia, relative to the sulfonylureas, by emulating target trials in electronic health records of diabetic patients at an academic-centered healthcare system in the US and a wide-ranging group of primary care practices in the UK. To address metformin’s potentially dual influences on dementia risk—that it might reduce the hazard of death and put more people at risk of developing dementia while reducing the hazard of dementia by slowing biological aging, we used a competing risks approach and carefully grounded that within a causal inference emulated trial framework. To identify candidate biomarkers of metformin’s actions in the brain that might mediate reduced dementia risk, we conducted an in-vitro systems pharmacology evaluation of metformin and glyburide on differentiated human neural cells through differential gene expression. We named our multi-dimensional approach DRIAD-EHR (Drug Repurposing in Alzheimer’s Disease-Electronic Health Records). In intention-to-treat analyses, metformin was associated with a lower hazard of all-cause mortality than sulfonylureas in both cohorts. In competing risks analyses, there was also a lower cause-specific hazard of dementia onset among metformin initiators. In in-vitro studies, metformin reduced human neural cell expression of SPP1 and APOE, two secreted proteins that have been implicated in Alzheimer’s disease pathogenesis and whose levels can be quantified in the CSF. Together, our findings suggest that metformin might prevent dementia in patients without type II diabetes. In addition, our results inform the design of clinical trials of metformin in non-diabetics and suggest a pharmacodynamic CSF biomarker, SPP1, for metformin’s action in the brain.

Competing Interest Statement

B.T.H. is a member of the SAB and owns shares in Dewpoint. He also serves on an advisory panel for Biogen, and his laboratory has current research funding from AbbVie. His wife is an employee and shareholder of Novartis. R.A.B. serves on an advisory board for Biogen. M.W.A. is a consultant for Transposon Rx and receives research support from IFF.

Funding Statement

We thank the NIH R01 AG058063 (awarded to M.W.A), P30 AG062421 (awarded to B.T.H.), a CART grant (awarded to M.W.A.), an administrative supplement to U54 CA22508 (awarded to M.W.A.), IBM Research (awarded to R.E.W. and S.N.F.), the Abdul Latif Jameel Clinic for Machine Learning in Health grant (awarded to R.E.W. and S.N.F.), the UK Dementia Research Institute which receives its funding from UK DRI Ltd, funded by the UK Medical Research Council (awarded to I.T.), the Alzheimer's Society and Alzheimer's Research UK, support by the British Heart Foundation Centre for Research Excellence at Imperial College (awarded to I.T.), the Hellenic Foundation for Research and Innovation (HFRI) (awarded to I.T.), and the General Secretariat for Research and Technology (GSRT) (awarded to I.T.) for support.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Use of RPDR data for this study was approved by the institutional review board (IRB) of MGB. Use of CPRD data for this study was approved by the Independent Scientific Advisory Committee (ISAC) for Medicines and Healthcare products Regulatory Agency (MHRA) database research (protocol number: 19_065R).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵^ Contact author with Journal

Data Availability

US RPDR. Researchers can obtain an anonymized version of the study dataset from the authors upon request and completion of the MGB Health data use agreement for the use of RPDR data. This agreement ensures the privacy of MGB patients and compliance with US regulatory standards and has been approved by the MGB IRB. UK CPRD. According to the UK Data Protection Act, information governance restrictions (to protect patient confidentiality) prevent data sharing via public deposition. Therefore, CPRD data that support the findings of this study are not publicly available. Data extracts can be requested by applying to the Clinical Practice Research Datalink for data spanning the years 2000 to 2018 (https://www.cprd.com). The code to process the data is available from the authors upon request. Metformin/Glyburide RNA-seq. https://www.synapse.org/#!Synapse:syn22213067

https://www.synapse.org/#!Synapse:syn22213067

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted August 12, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Drug repurposing of metformin for Alzheimer’s disease: Combining causal inference in medical records data and systems pharmacology for biomarker identification
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Drug repurposing of metformin for Alzheimer’s disease: Combining causal inference in medical records data and systems pharmacology for biomarker identification
Marie-Laure Charpignon, Bella Vakulenko-Lagun, Bang Zheng, Colin Magdamo, Bowen Su, Kyle Evans, Steve Rodriguez, Artem Sokolov, Sarah Boswell, Yi-Han Sheu, Melek Somai, Lefkos Middleton, Bradley T. Hyman, Rebecca A. Betensky, Stan N. Finkelstein, Roy E. Welsch, Ioanna Tzoulaki, Deborah Blacker, Sudeshna Das, Mark W. Albers
medRxiv 2021.08.10.21261747; doi: https://doi.org/10.1101/2021.08.10.21261747
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Drug repurposing of metformin for Alzheimer’s disease: Combining causal inference in medical records data and systems pharmacology for biomarker identification
Marie-Laure Charpignon, Bella Vakulenko-Lagun, Bang Zheng, Colin Magdamo, Bowen Su, Kyle Evans, Steve Rodriguez, Artem Sokolov, Sarah Boswell, Yi-Han Sheu, Melek Somai, Lefkos Middleton, Bradley T. Hyman, Rebecca A. Betensky, Stan N. Finkelstein, Roy E. Welsch, Ioanna Tzoulaki, Deborah Blacker, Sudeshna Das, Mark W. Albers
medRxiv 2021.08.10.21261747; doi: https://doi.org/10.1101/2021.08.10.21261747

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1747)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (653)
  • Epidemiology (10780)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2933)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1918)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12496)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (321)
  • Neurology (2780)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (554)
  • Occupational and Environmental Health (597)
  • Oncology (1454)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (379)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2630)
  • Public and Global Health (5338)
  • Radiology and Imaging (1002)
  • Rehabilitation Medicine and Physical Therapy (594)
  • Respiratory Medicine (722)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)